=Pacific Biosciences (PACB) to be acquired by Illumina (ILMN) for $8.00/share

• Update Jan 02, 2020 NEW YORK – Gene sequencing company Illumina abandons $1.2 billion deal to buy rival Pacific Biosciences. Antitrust authorities in the U.S. and U.K. had been scrutinizing the deal, the companies said. 
• Illumina would pay Pacific Biosciences $98 million for the terminated deal, which was announced in 2018 and had attracted scrutiny from antitrust authorities in the United States and UK, both the companies said in a joint statement.
  

*****

• Oct. 30: #1, 5; vol. 777K

Pacific Biosciences to be acquired by Illumina (ILMN) for $8.00/share in cash, or approximately $1.2 bln
With its acquisition of Pacific Biosciences, Illumina will be positioned to provide integrated workflows and novel innovations that bring together the best of both technologies to help researchers advance their discoveries faster and clinicians offer new tests economically. The transaction is subject to approval by the shareholders of Pacific Biosciences, as well as other customary closing conditions, including applicable regulatory approvals. Illumina expects to close the transaction in mid-2019.

Pacific Biosciences misses by $0.04, misses on revs;

Reports Q3 (Sep) loss of $0.19 per share, $0.04 worse than the S&P Capital IQ Consensus of ($0.15); revenues fell 22.9% year/year to $18.16 mln vs the $22.39 mln S&P Capital IQ Consensus.

Illumina (ILMN) will acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction. This price represents a premium of 71% to Pacific Biosciences' 30 trading day volume weighted average share price as of the market close on October 31st, 2018, and a total enterprise value of approximately $1.2 billion on a fully diluted basis.